# Tirzepatide: Did people lose more weight?

> Tirzepatide: What did the comparisons find? — Research Peptide Fundamentals research peptides: tirzepatide copies GIP and GLP-1, hormones released after food. See findings and side effects.

**03 / two hormones after meals**

Scientists copied two meal hormones to make tirzepatide. Direct tests showed a larger fall in weight than semaglutide, alongside stomach and gallbladder concerns.

## What is the short answer about tirzepatide?

The design of tirzepatide copies GIP and GLP-1, hormones released after meals to help control sugar. Studies tested the drug in many people, and approval covers specific medical uses.

Those patients had type 2 diabetes or obesity, excess body fat that raises health risks. In obesity, the direct test found that average weight fell further with tirzepatide than semaglutide [8].

Your question about other illnesses still needs studies that test those illnesses directly. Losing more weight doesn't tell you which drug better prevents heart trouble or kidney disease.

SURPASS-2 tested people with diabetes and favored tirzepatide for weight and blood-sugar changes [16]. You get sugar levels over time from that blood test, beyond a single day's reading.

Major studies found that stomach and bowel problems were reported more often than other side effects [15][16]. A large weight change doesn't mean that everyone found the drug easy to take.

The review left doubt about pancreatitis, when the pancreas gland becomes inflamed [14]. The total of gallbladder and related drainage-tube problems increased, though separate counts left more doubt.

## How was tirzepatide made to act for longer?

Scientists based tirzepatide on GIP, a hormone whose job includes controlling sugar in blood after meals. The drug has a 39-amino-acid chain; amino acids are small parts also used to make proteins.

An added piece of fat helps the drug hold onto a protein in blood. The added fat is part of the manufactured drug and slows removal from your body.

The drug acts at receptors, places on cells where hormone messages are received. The cells respond to GIP and GLP-1, hormones involved in controlling sugar after food.

For type 2 diabetes, tirzepatide gained the first drug approval for copying both hormone actions [13]. Those actions help explain its benefits, but don't settle every claim about treatment.

You need the country and date when checking which medical uses have approval. Approval also can't prove the unchecked research bottle's strength, contents, or cleanliness.

Trial medicines and approved drugs have checks on how they're made and tested. A research bottle named after the drug doesn't necessarily have matching checks or evidence.

The findings here can help you understand what happened to people in published studies. They don't provide study places or personal instructions for preparing material or giving treatment.

## What do the two hormone actions change after meals?

Tirzepatide copies GIP and GLP-1, hormones released after food to help control sugar. When blood sugar rises, both help release insulin, the hormone that helps cells use sugar taken from blood.

GLP-1 also holds back glucagon, a hormone that tells the body to release sugar. Food leaves your stomach more slowly, and the brain changes how hungry you feel.

Together these actions can help people eat less and lower their blood sugar. You still need studies to see whether those changes help with a particular illness.

SURPASS-2 compared the drugs directly in adults with type 2 diabetes. Tirzepatide improved weight and the blood test of longer-term sugar levels more than semaglutide [16].

SURMOUNT-5 also compared weight loss directly and found a larger change with tirzepatide [8]. You can't take those results as proof of every other benefit someone might claim.

Slower movement of food through the stomach helps explain nausea, vomiting, and diarrhea. The actions that reduce hunger can also make the drug difficult for some people to take.

## What did the weight tests and the safety review find?

SURMOUNT-5 studied 751 adults without type 2 diabetes who had obesity. At 72 weeks, average weight fell by 20.2% with tirzepatide and 13.7% with semaglutide [8].

Testing both drugs together gives you a fairer weight comparison because unrelated studies may involve different patients, different hospital care, and different chances of improvement before any medicine is given. The direct result still concerns the patients, treatments, and follow-up time of that particular study.

SURMOUNT-1 studied 2,539 adults who didn't have diabetes and had either obesity or a weight-related illness alongside being overweight. Different tirzepatide amounts gave average weight losses of 15.0% to 20.9% at 72 weeks, against 3.1% with placebo [15].

Placebo treatment lacks the active drug, helping show changes that could happen without the drug. Stomach and bowel trouble was mostly mild to moderate, especially as treatment was increased.

SURPASS-2 compared treatments in 1,879 adults with type 2 diabetes. Tirzepatide improved weight and longer-term blood sugar more, with stomach and bowel side effects again common [16].

Nine trials, involving 9,871 people, were reviewed together to check uncommon pancreas illness, with doubt remaining. An inflamed pancreas, called pancreatitis, wasn't clearly more common, but the possibility of increased risk remained [14].

Gallbladder and bile-duct problems were more common when counted together; bile ducts carry digestive fluid to the bowel from two organs, the gallbladder and liver. Adding cases made the increase clearer, while the smaller counts for each kind left more doubt.

## What could make treatment difficult or unsafe?

**Research users tell these personal accounts; studies comparing treatments haven't confirmed the reported experiences.** People mention less hunger, less thinking about food, weight loss, steadier blood sugar, or easier movement.

Some describe more energy, while others describe tiredness or weight loss that stops progressing. Reports also include nausea, constipation, diarrhea, changed tastes, unwanted foods, sore shot sites, and hair shedding.

You can't calculate how often a change happens from those personal reports. Other care and expectations may help explain what people notice while using a substance.

Stomach and bowel complaints were most common when trial treatment amounts were being increased [15][16]. Those complaints made treatment difficult even when the drug was helping with weight.

The review left substantial doubt about pancreatitis, an inflamed pancreas, without clearly showing more cases [14]. You still can't rule out an increase in that uncommon harm from the review.

Gallbladder and related drainage-tube problems increased when researchers added all those cases together [14]. There were fewer cases of each separate kind, leaving the review unable to say which kind increased.

Taking another blood-sugar drug alongside tirzepatide can make blood sugar fall too low. Slower stomach emptying also needs medical assessment; the safety reference doesn't replace a doctor assessing your health [13].

Your other medicines, planned surgery, birth control, and side effects affect treatment decisions. A doctor needs to assess those details with you, beyond the findings in a study summary.

## Does more weight loss mean more benefit for every illness?

For obesity and type 2 diabetes, direct tests set tirzepatide against [semaglutide](/semaglutide) [8][16]. You get a firmer comparison when both drugs are tested together under the same study conditions.

Your answer still has limits from the patients, treatment amounts, and length of follow-up. Knowing which drug was given may also change what people expect and report.

Semaglutide had separate tests in different patient groups for kidney disease and serious heart trouble [9][10]. The weight test SURMOUNT-5 doesn't show that tirzepatide also did better for those illnesses.

[Thymosin alpha-1](/thymosin-alpha-1) and [PT-141](/pt-141) were tested for quite different problems. Their results don't let you rank all the drugs as if they treated one illness.

Countries may approve different uses or describe warnings differently after reading the same evidence. Your approval question needs the country and the medical use you're asking about.

The [side-by-side findings](/compare) keep each answer beside the people and problems studied. You can assess a claim using those details while keeping the answer within the study's limits.

![Tirzepatide research illustration](/images/tirzepatide.webp)

---

An independent desk for comparing peptide trial claims across regions—no recruitment, no retail, and no medical advice.